Ftse Mib
33.629,21
-0,32%
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
NASDAQ
16.156,33
1,99%
Bitcoin
63.528,31
-0,56%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Vaxcyte Inc (PCVX) Vaxcyte Inc (PCVX) Notizie

Vaxcyte Inc

PCVX
65,96
1,41 (2,18%)
04 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
02/4/202422:05GLOBEVaxcyte to Present at the 23rd Annual Needham Virtual..
05/3/202403:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202403:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202403:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202414:30GLOBEVaxcyte Completes Enrollment of Phase 2 Study Evaluating..
01/3/202422:02EDGAR2Form 144 - Report of proposed sale of securities
01/3/202422:00EDGAR2Form 144 - Report of proposed sale of securities
27/2/202422:58EDGAR2Form S-8 - Securities to be offered to employees in employee..
27/2/202422:02EDGAR2Form 8-K - Current report
27/2/202422:01GLOBEVaxcyte Reports Fourth Quarter and Full Year 2023 Financial..
20/2/202422:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202422:05GLOBEVaxcyte to Report Fourth Quarter and Full Year 2023..
05/2/202423:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202423:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/2/202400:39GLOBEVaxcyte Announces Closing of $862.5 Million Public Offering..
01/2/202422:07EDGAR2Form 144 - Report of proposed sale of securities
01/2/202422:06EDGAR2Form 144 - Report of proposed sale of securities
01/2/202422:05GLOBEVaxcyte to Present at the Guggenheim Healthcare Talks | 6th..
31/1/202423:26EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
31/1/202423:19EDGAR2Form 8-K - Current report
31/1/202405:37GLOBEVaxcyte Announces Pricing of $750 Million Public Offering
30/1/202422:13EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
30/1/202422:01GLOBEVaxcyte Announces Commencement of Proposed Public Offering..
29/1/202414:30GLOBEVaxcyte Completes Enrollment of Phase 1/2 Study Evaluating..
16/1/202422:01GLOBEVaxcyte Appoints Whitney Jones as Chief People Officer
04/1/202422:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202422:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202422:01GLOBEVaxcyte Provides Clinical and Regulatory Progress Update on..
02/1/202422:04EDGAR2Form 144 - Report of proposed sale of securities
02/1/202422:03EDGAR2Form 144 - Report of proposed sale of securities
11/12/202322:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/12/202322:15EDGAR2Form 144 - Report of proposed sale of securities
05/12/202322:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/12/202300:35GLOBEVAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in..
01/12/202322:12EDGAR2Form 144 - Report of proposed sale of securities
29/11/202322:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/11/202322:46EDGAR2Form 3 - Initial statement of beneficial ownership of..
28/11/202314:32EDGAR2Form 8-K - Current report
28/11/202314:30GLOBEVaxcyte Appoints Jacks Lee to Board of Directors
27/11/202322:05EDGAR2Form 8-K - Current report
27/11/202322:00GLOBEVaxcyte Exercises Option and Enters into Manufacturing..
09/11/202314:30GLOBEVaxcyte Doses First Participants in Phase 1/2 Clinical Study..
06/11/202322:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/11/202322:07EDGAR2Form 8-K - Current report
06/11/202322:03GLOBEVaxcyte Reports Third Quarter 2023 Financial Results and..
03/11/202321:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/11/202321:07EDGAR2Form 144 - Report of proposed sale of securities
31/10/202321:05GLOBEVaxcyte to Present at Upcoming Investor Conferences
19/10/202315:29DJNVaxcyte Gets FDA Go-Ahead on Pneumococcal Vaccine..
19/10/202314:30GLOBEVaxcyte Announces FDA Clearance of Investigational New Drug..
Apertura: 66,48 Min: 65,46 Max: 67,08
Chiusura: 64,55

La tua Cronologia

NASDAQ
PCVX
Vaxcyte
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network